DIHYDROPYRIDINE CALCIUM ANTAGONISTS: THE ROLE IN CURRENT THERAPY OF CARDIO-VASCULAR DISEASES

Classification of calcium antagonists (CA) is presented. Results of the large clinical trials (STONE, STOP-Hypertension-2, ALLHAT, ASCOT-BPLA etc.) devoted to estimation of CA effects on the risk of cardiovascular complications are analyzed. The significant place of dihydropyridine CA in current gui...

Full description

Saved in:
Bibliographic Details
Published inRat͡s︡ionalʹnai͡a︡ farmakoterapii͡a︡ v kardiologii Vol. 4; no. 2; pp. 53 - 57
Main Authors Shilova, E. V., Martsevich, S. Y.
Format Journal Article
LanguageEnglish
Published Столичная издательская компания 01.01.2008
Subjects
amlodipine
arterial hypertension
calcium antagonists
cardiovascular risk
dihydropiridines
ischemic heart disease
Online AccessGet full text

Cover

More Information
Summary:Classification of calcium antagonists (CA) is presented. Results of the large clinical trials (STONE, STOP-Hypertension-2, ALLHAT, ASCOT-BPLA etc.) devoted to estimation of CA effects on the risk of cardiovascular complications are analyzed. The significant place of dihydropyridine CA in current guidelines on arterial hypertension and ischemic heart disease therapy is underlined. Results of a pilot study on comparison of two amlodipines (original Norvasc and generic Stamlo M) are discussed.
ISSN:1819-6446
2225-3653
DOI:10.20996/1819-6446-2008-4-2-53-57